ARTICLE | Company News
FDA approves Gilead's Genvoya for HIV
November 6, 2015 3:27 AM UTC
FDA approved Genvoya tenofovir alafenamide fumarate (TAF)/elvitegravir/cobicistat/emtricitabine from Gilead Sciences Inc. (NASDAQ:GILD) to treat HIV-1 infection in patients ages 12 and older.
Gilead plans to launch the drug next week at an annual wholesale acquisition cost (WAC) of $31,362. ...